Surgery and cancer promotion: are we trading beauty for cancer?

• Published in: QJM : An International Journal of Medicine 2011-09, Vol.104 (9), p.811-815
• Main Authors: Goldstein, M R, Mascitelli, L
• Format: Article
• Language: English
• Subjects: Adrenergic beta-Antagonists - therapeutic use; Cell Transformation, Neoplastic; Female; Humans; Male; Neoplasms - etiology; Neoplasms - prevention & control; Reconstructive Surgical Procedures - adverse effects; Stress, Physiological; Surgical Procedures, Operative - adverse effects
• ISSN: 1460-2725; 1460-2393
• DOI: 10.1093/qjmed/hcr039

It is well-known that cancer surgery can actually promote the growth of some tumors by a variety of mechanisms. There are observational data suggesting that surgery per se can increase the risk of cancer among individuals without a history of clinical cancer. Occult microscopic cancers are exceedingly common in the general population and are held in a dormant state by a balance between cell proliferation and cell death and also an intact host immune surveillance. The catecholamine surge from the stress of surgery and resulting β(2)-adrenergic signaling culminates in a transient and robust increased vascular endothelial growth factor expression locally and systemically that is enough to start tumor angiogenesis and end dormancy. The same catecholamine surge and β(2)-adrenergic signaling impairs cell-mediated immunity at a crucial time. Elegant animal studies have demonstrated that perioperative nonselective β-blockade abrogates surgical stress-induced angiogenesis and tumor growth. Prospective human trials are desperately needed and clinical implications are discussed.